VERAXA Biotech (NASDAQ: VRXA) Is ‘One to Watch’

Published Jun 12, 2026, 5:00 PM

VERAXA is advancing a diversified oncology pipeline spanning monoclonal antibodies, antibody-drug conjugates, bispecific ADCs and proprietary BiTAC-based therapeutic formats across multiple cancer indications.
The company’s proprietary BiTAC platform is designed to conditionally activate therapeutic activity at tumor sites, with the goal of improving target specificity while reducing off-tumor toxicity.
Through its focus on ADCs and TCEs, VERAXA is positioned within two rapidly growing segments of the global oncology therapeutics market.
Via selected partnerships, VERAXA aims to contribute value to developments in complementary therapeutic sectors such as radioimmunoconjugates (“RICs”) and antibody-oligonucleotide conjugates (“AOCs”).

VERAXA Biotech has successfully concluded a business combination with Voyager Acquisition Corp. (NASDAQ: VACH) and began trading on the NASDAQ Capital Market under the ticker symbol ‘VRXA’ on June 11, 2026.

VERAXA Biotech (NASDAQ: VRXA) is a biotechnology company focused on the discovery and development of a new generation of antibody-based therapeutics for the treatment of solid tumors. VERAXA’s vision is to deliver the next wave of smart cancer therapies with curative potential and…